Subtypes of atrial fibrillation with concomitant valvular heart disease derived from electronic health records: phenotypes, population prevalence, trends and prognosis.
Aged
Aged, 80 and over
Anticoagulants
/ therapeutic use
Atrial Fibrillation
/ drug therapy
Bioprosthesis
Cardiac Valve Annuloplasty
Cause of Death
Embolism
/ epidemiology
England
/ epidemiology
Factor Xa Inhibitors
/ therapeutic use
Female
Heart Valve Diseases
/ epidemiology
Heart Valve Prosthesis
Heart Valve Prosthesis Implantation
Hemorrhagic Stroke
/ epidemiology
Humans
Ischemic Stroke
/ epidemiology
Male
Middle Aged
Mortality
Phenotype
Prevalence
Prognosis
Proportional Hazards Models
Stroke
/ epidemiology
Warfarin
/ therapeutic use
Atrial fibrillation
Electronic health records
Mortality
Stroke
Systemic embolism
Valvular heart disease
Journal
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
ISSN: 1532-2092
Titre abrégé: Europace
Pays: England
ID NLM: 100883649
Informations de publication
Date de publication:
01 12 2019
01 12 2019
Historique:
received:
11
07
2019
accepted:
26
07
2019
pubmed:
14
8
2019
medline:
15
12
2020
entrez:
14
8
2019
Statut:
ppublish
Résumé
To evaluate population-based electronic health record (EHR) definitions of atrial fibrillation (AF) and valvular heart disease (VHD) subtypes, time trends in prevalence and prognosis. A total of 76 019 individuals with AF were identified in England in 1998-2010 in the CALIBER resource, linking primary and secondary care EHR. An algorithm was created, implemented, and refined to identify 18 VHD subtypes using 406 diagnosis, procedure, and prescription codes. Cox models were used to investigate associations with a composite endpoint of incident stroke (ischaemic, haemorrhagic, and unspecified), systemic embolism (SSE), and all-cause mortality. Among individuals with AF, the prevalence of AF with concomitant VHD increased from 11.4% (527/4613) in 1998 to 17.6% (7014/39 868) in 2010 and also in individuals aged over 65 years. Those with mechanical valves, mitral stenosis (MS), or aortic stenosis had highest risk of clinical events compared to AF patients with no VHD, in relative [hazard ratio (95% confidence interval): 1.13 (1.02-1.24), 1.20 (1.05-1.36), and 1.27 (1.19-1.37), respectively] and absolute (excess risk: 2.04, 4.20, and 6.37 per 100 person-years, respectively) terms. Of the 95.2% of individuals with indication for warfarin (men and women with CHA2DS2-VASc ≥1 and ≥2, respectively), only 21.8% had a prescription 90 days prior to the study. Prevalence of VHD among individuals with AF increased from 1998 to 2010. Atrial fibrillation associated with aortic stenosis, MS, or mechanical valves (compared to AF without VHD) was associated with an excess absolute risk of stroke, SSE, and mortality, but anticoagulation was underused in the pre-direct oral anticoagulant (DOAC) era, highlighting need for urgent clarity regarding DOACs in AF and concomitant VHD.
Identifiants
pubmed: 31408153
pii: 5549426
doi: 10.1093/europace/euz220
pmc: PMC6888023
doi:
Substances chimiques
Anticoagulants
0
Factor Xa Inhibitors
0
Warfarin
5Q7ZVV76EI
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1776-1784Subventions
Organisme : Department of Health
ID : CDF-2015-08-074
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K006584/1
Pays : United Kingdom
Organisme : Arthritis Research UK
Pays : United Kingdom
Organisme : Chief Scientist Office
Pays : United Kingdom
Organisme : Cancer Research UK
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.
Références
Europace. 2017 Nov 1;19(11):1757-1758
pubmed: 29096024
Eur Heart J. 2018 Apr 21;39(16):1481-1495
pubmed: 29370377
Eur Heart J. 2014 Dec 14;35(47):3328-35
pubmed: 25265975
J Am Soc Echocardiogr. 2009 Jan;22(1):1-23; quiz 101-2
pubmed: 19130998
Int J Epidemiol. 2015 Jun;44(3):827-36
pubmed: 26050254
J Am Heart Assoc. 2017 Dec 22;6(12):
pubmed: 29273635
Europace. 2016 Nov;18(11):1609-1678
pubmed: 27567465
Curr Med Res Opin. 2018 Feb;34(2):337-343
pubmed: 29065729
J Manag Care Pharm. 2013 May;19(4):302-16
pubmed: 23627576
Nat Rev Cardiol. 2011 Mar;8(3):162-72
pubmed: 21263455
Circulation. 2015 Oct 6;132(14):1320-8
pubmed: 26330414
J Public Health (Oxf). 2014 Dec;36(4):684-92
pubmed: 24323951
Eur Heart J. 2015 Jul 21;36(28):1822-30
pubmed: 25994754
Eur J Prev Cardiol. 2018 Sep;25(14):1485-1495
pubmed: 29966429
Heart. 2017 Nov;103(21):1696-1703
pubmed: 28432156
Circulation. 2014 Apr 15;129(15):1568-76
pubmed: 24463370
Lancet. 2014 May 31;383(9932):1899-911
pubmed: 24881994
Glob Heart. 2014 Mar;9(1):113-9
pubmed: 25432121
Int J Epidemiol. 2015 Feb;44(1):129-41
pubmed: 25416721
Int J Epidemiol. 2012 Dec;41(6):1625-38
pubmed: 23220717